CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues [Abstract]
Product sales	$ 0	$ 10,091,000	$ 0	$ 22,334,000
Operating expenses:
Cost of products	0	3,285,000	0	5,742,000
Research and development expenses	6,762,000	4,057,000	10,614,000	9,587,000
Selling, general and administrative expenses	15,174,000	7,095,000	26,186,000	15,008,000
Intangible asset amortization	0	203,000	0	406,000
Changes in fair value of contingent consideration	0	918,000	0	3,396,000
Gain on sale of Hospital Products	0	(45,760,000)	0	(45,760,000)
Restructuring costs (income)	0	24,000	(53,000)	183,000
Total operating expense (income)	21,936,000	(30,178,000)	36,747,000	(11,438,000)
Operating (loss) income	(21,936,000)	40,269,000	(36,747,000)	33,772,000
Investment and other income (expense), net	432,000	(741,000)	1,042,000	(1,119,000)
Interest expense	(1,930,000)	(3,237,000)	(3,859,000)	(6,427,000)
Gain from release of certain liabilities	88,000	0	166,000	0
Other expense - changes in fair value of contingent consideration payable	0	(125,000)	0	(435,000)
(Loss) income before income taxes	(23,346,000)	36,166,000	(39,398,000)	25,791,000
Income tax (benefit) expense	(3,765,000)	5,292,000	(6,372,000)	(4,218,000)
Net (loss) income	$ (19,581,000)	$ 30,874,000	$ (33,026,000)	$ 30,009,000
Net loss per share - basic (in dollars per share)	$ (0.33)	$ 0.57	$ (0.56)	$ 0.63
Net loss per share - diluted (in dollars per share)	$ (0.33)	$ 0.49	$ (0.56)	$ 0.58
Weighted average number of shares outstanding - basic (in shares)	58,488	54,272	58,465	47,665
Weighted average number of shares outstanding - diluted (in shares)	58,488	69,942	58,465	63,083